mRNA Nanoparticles Trigger Liver Regeneration Through Partial Reprogramming
Liver-targeted OSKM mRNA delivery induces regenerative progenitor cells and enhances recovery from acute liver injury in mice.
Summary
Researchers in South Korea have developed a liver-targeted lipid nanoparticle system that delivers Yamanaka factor mRNA (OSKM) directly to the liver, triggering a controlled partial reprogramming response. This causes mature liver cells to temporarily dedifferentiate into progenitor-like cells capable of supporting tissue repair. Using single-nucleus RNA sequencing, the team confirmed that one of the two progenitor cell populations generated closely resembles cells seen in both mouse and human livers after acetaminophen injury. Critically, the transient nature of mRNA delivery limits the safety concerns associated with viral or transgenic approaches, which risk prolonged factor expression and tumor formation. Treatment with OSKM mRNA nanoparticles before acetaminophen-induced liver damage significantly enhanced regeneration. This work positions temporary, targeted reprogramming as a realistic therapeutic strategy for acute liver failure and potentially broader organ regeneration.
Detailed Summary
Acute liver failure carries a high mortality rate and limited treatment options beyond transplantation. The emerging field of in vivo partial reprogramming offers a possible alternative — briefly rewinding cell identity to unlock regenerative capacity without permanently destabilizing tissue. This study advances that concept with a clinically relevant delivery system.
Researchers at Seoul National University and Yonsei University engineered lipid nanoparticles (LNPs) optimized for liver tropism, loading them with mRNA encoding the four Yamanaka transcription factors: Oct4, Sox2, Klf4, and c-Myc (OSKM). Unlike viral vectors or transgenic mouse models, mRNA is inherently transient — it degrades within days, sharply reducing the risk of sustained reprogramming that could drive tumor growth or loss of organ function.
In mouse experiments, OSKM mRNA-LNP treatment without prior injury generated two distinct liver progenitor-like cell (LPLC) populations. Single-nucleus RNA sequencing revealed that one population closely mirrors the injury-induced LPLCs found in acetaminophen-damaged mouse and human livers. Importantly, this reprogramming occurred with limited activation of injury-associated immune responses, suggesting a relatively clean biological signal.
When OSKM mRNA-LNPs were administered before acetaminophen-induced liver injury, the treated animals showed enhanced hepatic regeneration compared to controls. Sox9-positive LPLC-like cells — a known marker of hepatic progenitors — appeared following treatment, consistent with genuine dedifferentiation and progenitor induction.
For longevity science, these findings matter on two levels. First, they validate transient partial reprogramming as a safe and effective regenerative strategy in a solid organ. Second, the LNP-mRNA platform is inherently scalable and adaptable to human translation. Caveats include the preclinical mouse setting, reliance on abstract-level data only, and the unknown durability of the regenerative response in repeated or chronic injury contexts.
Key Findings
- Liver-targeted OSKM mRNA nanoparticles induced two distinct liver progenitor-like cell populations without requiring prior injury.
- One progenitor population closely matched injury-induced cells seen in acetaminophen-damaged mouse and human livers by single-nucleus RNA sequencing.
- OSKM mRNA-LNP treatment enhanced liver regeneration following acetaminophen injury compared to untreated controls.
- Transient mRNA delivery avoids prolonged reprogramming, reducing oncogenic and dedifferentiation safety risks vs. viral approaches.
- Sox9-positive progenitor-like cells appeared post-treatment, confirming genuine hepatocyte dedifferentiation.
Methodology
The study used liver-targeted lipid nanoparticles loaded with OSKM mRNA in mouse models, with and without acetaminophen-induced liver injury. Single-nucleus RNA sequencing was used to characterize induced progenitor cell populations and compare them to injury-derived counterparts in both mouse and human liver data. Functional regenerative outcomes were assessed following acute hepatotoxin challenge.
Study Limitations
This summary is based on the abstract only, as the full text is not open access. All experiments are preclinical (mouse models), and efficacy in human liver disease remains unestablished. Long-term safety, optimal dosing regimens, and effects of repeated treatments require further investigation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: